Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Will File sNDA For Zevalin In Follicular Lymphoma, CEO Bianco Tells DAILY

This article was originally published in The Pink Sheet Daily

Executive Summary

Improvement in progression-free survival is seen in patients with advanced follicular lymphoma following treatment with Zevalin.

You may also be interested in...



Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma

CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.

Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma

CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.

Cell Therapeutics Cuts Expenses As It Transforms Into Commercial Operation

CTI will reduce development staff as it shores up its commercial team ahead of Zevalin launch.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel